Eton Pharmaceuticals

ETON · NASDAQ

$50.19+$0.97 (+1.97%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $49.22

ETON analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy4
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $68.85 (+37.2% upside)

Low: $62.62
Now: $50.19
High: $73.50

Upgrades and downgrades

The latest rating actions, newest first

ETON analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Oct 14, 2026	Maintains	Buy	$70.00	43%
Canaccord Genuity	Aug 14, 2026	Maintains	Buy	$60.00 → $68.00	57%
B. Riley Securities	Aug 14, 2026	Maintains	Buy	$40.00 → $70.00	30%
HC Wainwright & Co.	Aug 14, 2026	Maintains	Buy	$65.00 → $70.00	43%
HC Wainwright & Co.	Aug 11, 2026	Maintains	Buy	$57.00 → $65.00	43%
Craig-Hallum	Jul 28, 2026	Maintains	Buy	$40.00 → $62.00	73%
Canaccord Genuity	Jul 17, 2026	Initiates	Buy	$60.00	57%
HC Wainwright & Co.	May 15, 2026	Maintains	Buy	$52.00 → $57.00	43%
B. Riley Securities	Mar 20, 2026	Maintains	Buy	$26.00 → $31.00	30%
HC Wainwright & Co.	Mar 20, 2026	Maintains	Buy	$37.00 → $52.00	43%

The case for and against

Updated Oct 15, 2026

Bull case

Eton Pharmaceuticals is demonstrating a strong fundamental inflection, with 2Q26 revenue of $37.6M and net income of $0.35 per diluted share both materially ahead of consensus, driven by HEMANGEOL’s faster-than-expected relaunch and ~95% patient conversion into the Eton Cares channel. Management’s raise of FY26 revenue guidance to at least $145M, alongside >35% FY26 adjusted EBITDA margin guidance and $26.8M of cash at quarter-end, signals operating leverage and balance-sheet flexibility to fund growth and acquisitions. The outlook is further supported by a de-risked late-stage pipeline and bolt-on strategy, including ASN-001, which addresses a larger 20,000-30,000 patient market and could become the portfolio’s largest revenue opportunity.

Bear case

Eton Pharmaceuticals is viewed negatively because, despite reporting positive GAAP net income for the first time in 3Q24, the company still has a history of operating losses and no assurance of sustained profitability. Its financial profile remains constrained by negative net cash of $4.1M, limited resources, and a reliance on PIPEs, public offerings, and expanded credit facilities, which raises dilution risk if positive cash flow does not persist. The outlook is also pressured by clinical, regulatory, commercial, collaboration, legal, and competition risks, while slower-than-expected adoption of its commercial and late-stage assets could materially weaken value creation.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.